Article Details

Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further ...

Retrieved on: 2021-03-08 12:56:15

Tags for this article:

Click the tags to see associated articles and topics

Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further .... View article details on hiswai:

Excerpt

Exelixis has exclusive license to panel of monoclonal antibodies against an undisclosed oncology target for biologics applications, leveraging WuXi ...

Article found on: www.biospace.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up